Novo Holdings A/S’s Enliven Therapeutics ELVN Stock Holding History

Novo Holdings A/S’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.8M	Sell	1,000,000 -280,000	-22%	-$11.9M	2.95%	10
2026 Q1	$50.2M	Sell	1,280,000 -200,000	-14%	-$5.54M	4.07%	8
2025 Q4	$22.8M	Buy	1,480,000 +53,740	+4%	+$1.07M	1.77%	20
2025 Q3	$29.2M	Buy	1,426,260 +341,828	+32%	+$6.89M	1.88%	18
2025 Q2	$21.8M	Buy	+1,084,432	New	+$20.5M	1.54%	20

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Novo Holdings A/S's ELVN Position: Q2 2026 in Review

Novo Holdings A/S reduced its Enliven Therapeutics (ELVN) stake by 22% in Q2 2026, selling an estimated $11.9M and leaving 1,000,000 shares worth $50.8M. The position accounts for 2.95% of the portfolio, ranked #10.

Novo Holdings A/S first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Novo Holdings A/S held 1,000,000 shares of Enliven Therapeutics worth $50.8M as of Q2 2026.
Novo Holdings A/S sold 280,000 Enliven Therapeutics shares in Q2 2026, an estimated $11.9M.
Enliven Therapeutics made up 2.95% of Novo Holdings A/S's portfolio in Q2 2026, its #10 holding.
Novo Holdings A/S first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.